The global tissue diagnostics market accounted for USD 5.57 billion in 2023 and is expected to reach at USD 11.92 billion by 2034 with a CAGR of 7.16% during the forecast period 2024-2034. Growing prevalence of cancer, elevated demand for precise disease diagnosis & monitoring, increasing utilization of liquid biopsy for detecting cancer, rising advancements in technology, surge in research & development investments, growing adoption of automated tissue-based diagnostic systems by research institutes, and rise in launch of innovative tissue diagnostics product are some of the key factors boosting the market growth.
Rise in launch of innovative tissue diagnostics product is predicted to boost the market growth during the forecast period. Tissue diagnostics entails the examination of small samples of bodily tissues to detect diseases such as cancer. Physicians obtain tissue samples through biopsies or surgical procedures, which are subsequently scrutinized under a microscope to identify any irregular cells or structures. This diagnostic method aids in providing precise diagnoses and guiding optimal treatment decisions for patients. For instance, in February 2023, F. Hoffman-La Roche Ltd. has released the ATRX rabbit polyclonal antibody and the IDH1 R132H (MRQ-67) rabbit monoclonal antibody for use in the BenchMark series of devices intended to detect brain tumors..
By technology, immunohistochemistry (IHC) was the highest revenue-grossing segment in the global tissue diagnostics market in 2023 owing to the rising utilization in the clinical research & development of cancer diagnostics & therapeutics, and increase in approvals by regulatory authorities. For instance, in April 2023, Leica Biosystems has disclosed that the BOND MMR Antibody Panel has received clearance from the US Food and Drug Administration (FDA) through the 510(k) process. This approval offers customers a robust option for IHC Mismatch Repair (MMR) screening in colorectal cancer patients, aiding in the potential identification of Lynch syndrome. Additionally, digital pathology & workflow is predicted to grow at the fastest CAGR during the forecast period owing to the growing trend among pathologists towards the adoption of whole-slide imaging (WSI). WSI technology is utilized to extract distinct tumor features and quantify each aspect, aiding in cancer diagnosis and offering valuable clinical insights into tumors.
By application, breast cancer was the highest revenue-grossing segment in the global tissue diagnostics market in 2023 owing to the significant rise in breast cancer cases, increased need for advanced diagnostic techniques. Research efforts are intensifying, supported by both governmental and private institutions, to develop more effective products for breast cancer diagnosis. Additionally, prostate cancer is predicted to grow at the fastest CAGR during the forecast period owing to the rising advancements in genomic technologies and surge in the introduction of new and innovative products. For instance, in March 2023, The QAi Prostate AI (Artificial Intelligence) module for the detection of prostate cancer has been released by Qritive. Prostate core needle biopsies are analyzed by QAi Prostate using complete slide pictures and sophisticated machine learning techniques.
By end-user, hospitals was the highest revenue-grossing segment in the global tissue diagnostics market in 2023 owing to the increasing utilization of tissue diagnostic solutions by hospitals, with physicians favoring tissue-based diagnostic testing techniques over traditional methods, and increase in the introduction of advanced products. For instance, in June 2022, Roche unveiled the VENTANA DP 600, a cutting-edge slide scanner that offers high capacity and enhances workflow flexibility in pathology labs. This scanner ensures ease of use and delivers superior image quality for stained histology slides from tissue samples. Additionally, contract research organizations (CROs) is predicted to grow at the fastest CAGR during the forecast period owing to the increase in clinical trials & extensive research in cancer therapy has notably increased the demand for services offered by Contract Research Organizations (CROs). These organizations provide research assistance and manage trials for companies and healthcare providers dealing with budget limitations.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing prevalence of cancer, the implementation of numerous public programs focused on reducing cancer rates, uptick in the utilization of sequencing technologies & healthcare IT systems within clinical operations, and increase in collaborations among key industry players. For instance, in January 2023, Accoya Biosciences, Inc. and Agilent Technologies, Inc. have teamed to develop multiplex-immunohistochemistry diagnostic solutions. Through this partnership, workflow solutions for multiplex assays customized for tissue analysis will be marketed with the purpose of providing a complete multiplex IHC solution for clinical research on biomarkers, made possible by digital pathology. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising need for cancer diagnosis, accompanied by expanded availability of various tissue diagnostic assays offered by global companies, and increase in partnerships among industry stakeholders. For instance, in October 2022, Hamamatsu Photonics K.K and Indica Labs have partnered to enhance integrated digital pathology workflows.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Rise in launch of innovative tissue diagnostics product is predicted to boost the market growth during the forecast period. Tissue diagnostics entails the examination of small samples of bodily tissues to detect diseases such as cancer. Physicians obtain tissue samples through biopsies or surgical procedures, which are subsequently scrutinized under a microscope to identify any irregular cells or structures. This diagnostic method aids in providing precise diagnoses and guiding optimal treatment decisions for patients. For instance, in February 2023, F. Hoffman-La Roche Ltd. has released the ATRX rabbit polyclonal antibody and the IDH1 R132H (MRQ-67) rabbit monoclonal antibody for use in the BenchMark series of devices intended to detect brain tumors..
By technology, immunohistochemistry (IHC) was the highest revenue-grossing segment in the global tissue diagnostics market in 2023 owing to the rising utilization in the clinical research & development of cancer diagnostics & therapeutics, and increase in approvals by regulatory authorities. For instance, in April 2023, Leica Biosystems has disclosed that the BOND MMR Antibody Panel has received clearance from the US Food and Drug Administration (FDA) through the 510(k) process. This approval offers customers a robust option for IHC Mismatch Repair (MMR) screening in colorectal cancer patients, aiding in the potential identification of Lynch syndrome. Additionally, digital pathology & workflow is predicted to grow at the fastest CAGR during the forecast period owing to the growing trend among pathologists towards the adoption of whole-slide imaging (WSI). WSI technology is utilized to extract distinct tumor features and quantify each aspect, aiding in cancer diagnosis and offering valuable clinical insights into tumors.
By application, breast cancer was the highest revenue-grossing segment in the global tissue diagnostics market in 2023 owing to the significant rise in breast cancer cases, increased need for advanced diagnostic techniques. Research efforts are intensifying, supported by both governmental and private institutions, to develop more effective products for breast cancer diagnosis. Additionally, prostate cancer is predicted to grow at the fastest CAGR during the forecast period owing to the rising advancements in genomic technologies and surge in the introduction of new and innovative products. For instance, in March 2023, The QAi Prostate AI (Artificial Intelligence) module for the detection of prostate cancer has been released by Qritive. Prostate core needle biopsies are analyzed by QAi Prostate using complete slide pictures and sophisticated machine learning techniques.
By end-user, hospitals was the highest revenue-grossing segment in the global tissue diagnostics market in 2023 owing to the increasing utilization of tissue diagnostic solutions by hospitals, with physicians favoring tissue-based diagnostic testing techniques over traditional methods, and increase in the introduction of advanced products. For instance, in June 2022, Roche unveiled the VENTANA DP 600, a cutting-edge slide scanner that offers high capacity and enhances workflow flexibility in pathology labs. This scanner ensures ease of use and delivers superior image quality for stained histology slides from tissue samples. Additionally, contract research organizations (CROs) is predicted to grow at the fastest CAGR during the forecast period owing to the increase in clinical trials & extensive research in cancer therapy has notably increased the demand for services offered by Contract Research Organizations (CROs). These organizations provide research assistance and manage trials for companies and healthcare providers dealing with budget limitations.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing prevalence of cancer, the implementation of numerous public programs focused on reducing cancer rates, uptick in the utilization of sequencing technologies & healthcare IT systems within clinical operations, and increase in collaborations among key industry players. For instance, in January 2023, Accoya Biosciences, Inc. and Agilent Technologies, Inc. have teamed to develop multiplex-immunohistochemistry diagnostic solutions. Through this partnership, workflow solutions for multiplex assays customized for tissue analysis will be marketed with the purpose of providing a complete multiplex IHC solution for clinical research on biomarkers, made possible by digital pathology. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising need for cancer diagnosis, accompanied by expanded availability of various tissue diagnostic assays offered by global companies, and increase in partnerships among industry stakeholders. For instance, in October 2022, Hamamatsu Photonics K.K and Indica Labs have partnered to enhance integrated digital pathology workflows.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Technology, Application, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Tissue Diagnostics Market Report 2023 - 2034
Tissue Diagnostics Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Primary & Special Staining
- In Situ Hybridization
- Software
- Consumables
- Instruments
- Digital Pathology and Workflow
- Information Management System Storage & Communication
- Image Analysis Informatics
- Whole Slide Imaging
- Immunohistochemistry
- Consumables
- Reagents
- Kits
- Antibodies
- Instruments
- Tissue Processing Systems
- Slide Staining Systems
- Slide Scanners
- Tissue Microarrays
- Other Products
- Anatomic Pathology
- Consumables
- Probes & Kits
- Reagents & Antibodies
- Others
- Instruments
- Tissue Processors
- Automatic Strainers
- Microtomes & Cryostat Microtomes
- Other Products
Tissue Diagnostics Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Non-small Cell Lung Cancer
- Gastric Cancer
- Prostate Cancer
- Breast Cancer
- Other Cancers
Tissue Diagnostics Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Pharmaceutical Organizations
- Hospitals
- Contract Research Organizations (CROs)
- Research Laboratories
Tissue Diagnostics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Tissue Diagnostics Market: Technology Estimates & Trend Analysis
8. Tissue Diagnostics Market: Application Estimates & Trend Analysis
9. Tissue Diagnostics Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Tissue Diagnostics Market
12. Europe Global Tissue Diagnostics Market
13. Asia Pacific Global Tissue Diagnostics Market
14. Latin America Global Tissue Diagnostics Market
15. MEA Global Tissue Diagnostics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Abbott Laboratories
- bioMérieux SA
- Thermo Fisher Scientific Inc.
- Danaher
- DiaGenic ASA
- QIAGEN
- F. Hoffmann-La Roche Ltd.
- BD
- Merck KGaA
- BioGenex
- Siemens
- Agilent Technologies
- GE Healthcare
- Bio SB
- Cell Signaling Technology Inc.
